Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma

Cancers

GiuseppeLuigi Banna¹  Diego Cortinovis²  Francesca Colonese²  Stefania Canova²  Maria Gemelli²  Paolo Bidoli²  StephenV. Liu³  Alessandro Morabito⁴  MariaLuisa Lavitrano⁵ 

[1]Department of Oncology, Portsmouth Hospitals University NHS Trust, Cosham, Portsmouth PO6 3LY, UK

[2]Dept Medical Oncology—ASST-Monza Ospedale San Gerardo, via Pergolesi 33, 20090 Monza, Italy

[3]Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC 20007, USA

[4]SC Oncologia Medica Toraco-Polmonare, IRCCS Istituto Nazionale dei Tumori, Fondazione Pascale, 80100 Napoli, Italy

[5]School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy

关键词: small cell lung cancer;    chemotherapy;    immunotherapy;    lurbinectedin;   

DOI  :  10.3390/cancers13051152

来源: DOAJ

【 摘 要 】

Small cell lung cancer (SCLC) is one of the deadliest thoracic neoplasms, in part due to its fast doubling time and early metastatic spread. Historically, cytotoxic chemotherapy consisting of platinum–etoposide or anthracycline-based regimens has demonstrated a high response rate, but early chemoresistance leads to a poor prognosis in advanced SCLC. Only a fraction of patients with limited-disease can be cured by chemo-radiotherapy. Given the disappointing survival rates in advanced SCLC, new cytotoxic agents are eagerly awaited. Unfortunately, few novel chemotherapy drugs have been developed in the latest decades. This review describes the results and potential application in the clinical practice of novel chemotherapy agents for SCLC.

【 授权许可】

Unknown